MoonLake Immunotherapeutics is a clinical-stage company developing sonelokimab, a Nanobody that blocks IL-17A and IL-17F, for hidradenitis suppurativa and psoriatic arthritis; it is not approved.
MoonLake's case rests on sonelokimab, an IL-17A and IL-17F blocker, in hidradenitis suppurativa, where Phase 3 VELA-1 met its primary endpoint but VELA-2 narrowly missed under the main analysis. MoonLake submitted the BLA on September 30, 2026, and expects FDA to say whether it accepts the filing within about 60 days. Cash was $537.0 million at June 30, with up to $400 million more available from Hercules and runway expected to mid-2028.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: FDA accepts the BLA for review
Does FDA accept the sonelokimab BLA, and on what timeline?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
MoonLake submitted sonelokimab's BLA in hidradenitis suppurativa on September 30; FDA's acceptance and review timeline are due by mid-December
Sonelokimab's BLA submission in HS and Phase 3 PsA readout test whether best-in-class IL-17A/F inhibition translates to regulatory approval and label breadth
Sonelokimab's BLA submission in HS tests whether mixed VELA data and a differentiated IL-17A/F profile can secure approval in a field where secukinumab and bimekizumab already compete
Sonelokimab's HS BLA hinges on FDA accepting VELA-2's treatment policy endpoint after the composite primary missed at p=0.053
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Skin diseases, Autoimmune and inflammatory diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
6 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.